Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody

Abdel-Nabi, Hani; Schwartz, Alan N.; Wechter, Debra G.; Higano, Celestia S.; Ortman-Nabi, Judith A.; Unger, Michael

doi:10.1007/bf01658982

Cited by 10 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although RAIDs have been successfully applied to several kinds of malignant tumors in organs such as colon, [2][3][4] lung, 12) and others, 13) there have been few studies on pancreatic cancer. 14,15) 111 In usually accumulates nonspecifically in the reticuloendothelial system, such as liver, spleen and bone marrow. DTPA is usually excreted from kidney.…”

Section: Discussionmentioning

confidence: 99%

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2

Sawada¹,

Nishihara²,

Yamamoto³

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2

Sawada¹,

Nishihara²,

Yamamoto³

et al. 1999

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…For example, 111 In-labeled ZCE-025 (an anti-CEA mAb that does not react with normal granulocyte glycoproteins) was investigated in several studies for the detection of primary, metastatic, or recurrent colorectal carcinomas (Abdel-Nabi et al 1988; Abdel-Nabi et al 1991; Kramer et al 1988; Patt et al 1988; Patt et al 1990). Imaging in patients with rising CEA levels successfully detected metastatic colorectal cancer that could not be detected by other methods, therefore changing patient management in many cases.…”

Section: Spect and Gamma Camera Imagingmentioning

confidence: 99%

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen

2008

View full text Add to dashboard Cite

Carcinoembryonic antigen (CEA), highly expressed in many cancer types, is an important target for cancer diagnosis and therapy. Radionuclide-based imaging techniques (gamma camera, single photon emission computed tomography [SPECT] and positron emission tomography [PET]) have been extensively explored for CEA-targeted cancer imaging both preclinically and clinically. Briefl y, these studies can be divided into three major categories: antibody-based, antibody fragment-based and pretargeted imaging. Radiolabeled anti-CEA antibodies, reported the earliest among the three categories, typically gave suboptimal tumor contrast due to the prolonged circulation life time of intact antibodies. Subsequently, a number of engineered anti-CEA antibody fragments (e.g. Fab', scFv, minibody, diabody and scFv-Fc) have been labeled with a variety of radioisotopes for CEA imaging, many of which have entered clinical investigation. CEA-Scan (a 99m Tc-labeled anti-CEA Fab' fragment) has already been approved by the United States Food and Drug Administration for cancer imaging. Meanwhile, pretargeting strategies have also been developed for CEA imaging which can give much better tumor contrast than the other two methods, if the system is designed properly. In this review article, we will summarize the current state-of-the-art of radionuclide-based cancer imaging targeting CEA. Generally, isotopes with short half-lives (e.g. 18F and 99m Tc) are more suitable for labeling small engineered antibody fragments while the isotopes with longer half-lives (e.g. 123I and 111 In) are needed for antibody labeling to match its relatively long circulation half-life. With further improvement in tumor targeting effi cacy and radiolabeling strategies, novel CEA-targeted agents may play an important role in cancer patient management, paving the way to "personalized medicine".

show abstract

Distribution of111in- and125i-labeled monoclonal antibody 17-1a in mice bearing xenografts of human pancreatic carcinoma hup-t4

Maeda¹,

Miyake²,

Kawagoshi³

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. The prognosis of pancreatic adenocarcinoma still remains poor because of the lack of reliable diagnostic tests for early stages of the disease. Monoclonal antibody 17‐1A(MoAb 17‐1A) has been studied extensively, and the antigen recognized by MoAb 17‐1A is expressed by adenocarcinomas of the pancreas and stomach, as well as other normal and malignant epithelial tissues. The potential of MoAb 17‐1A was investigated for its ability to detect pancreatic carcinomas. The use of MoAb 17‐1A in treatment also was studied. Methods. Immunoreactivity of MoAb 17‐1A with human pancreatic carcinoma cell line HuP‐T4 was examined histochemically by the avidin‐biotinylated enzyme complex method. MoAb 17‐1A was labeled with 125I by the Iodogen method and 111In using either diethylenetriaminepentaacetic anhydride (cDTPA) or 1‐(p‐benzyldiazonium) diethylenetriaminepentaacetic acid (aDTPA). After injection in nude mice bearing HuP‐T4 xenografts, the biodistribution of 111In‐ and 125I‐labeled MoAb 17‐1A was examined at various time points. Results. Positive staining of MoAb 17‐1A was noted for HuP‐T4 cells. A statistically significant (P < 0.01) greater tumor uptake was observed at 3 days after intravenous injection of 125I‐labeled MoAb 17‐1A when compared with 125I‐labeled nonspecific immunoglobulin G. 125I‐ and 111In‐labeled MoAb 17‐1A was concentrated in HuP‐T4 carcinoma 1.9–4.8 times higher than in the spleen, heart, liver, and pancreas. Conclusions. MoAb 17‐1A was found to bind selectively to human pancreatic carcinoma HuP‐T4. Tumor exhibited higher uptake of radiolabeled MoAb 17‐1A compared with adjacent normal tissues. These results suggest that MoAb 17‐1A may be applicable to the radioimmunodetection and radioimmunotherapy of pancreatic adenocarcinomas. Cancer 1994; 73:800–7.

show abstract

Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody

Cited by 10 publications

References 19 publications

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen

Distribution of111in- and125i-labeled monoclonal antibody 17-1a in mice bearing xenografts of human pancreatic carcinoma hup-t4

Contact Info

Product

Resources

About

Scintigraphic detection of gastric and pancreatic carcinomas with In‐111 ZCE 025 monoclonal antibody

Cited by 10 publications

References 19 publications

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by 111In‐labeled Chimeric Monoclonal Antibody Nd2

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by 111In‐labeled Chimeric Monoclonal Antibody Nd2

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen

Distribution of111in- and125i-labeled monoclonal antibody 17-1a in mice bearing xenografts of human pancreatic carcinoma hup-t4

Contact Info

Product

Resources

About

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2

Preoperative Clinical Radioimmunodetection of Pancreatic Cancer by ¹¹¹In‐labeled Chimeric Monoclonal Antibody Nd2